You are here: Industry Insights > Spinoff

News List

Mallinckrodt postpones split-up plan as opioid lawsuits cloud spinoff's future fiercepharma
August 07, 2019
Mallinckrodt thought it had a plan to rehabilitate its image, rid itself of low-performing products and banish at least some of its legal problems. But now it's put that plan on hold.
Novartis' Sandoz chief exits with 'de-integration' undone. Could a spinoff be next? fiercepharma
March 15, 2019
Novartis CEO Vas Narasimhan said in January that his company is focused on the “de-integration” of Sandoz from the rest of its operations.
Mallinckrodt spinoff to include 7 manufacturing sites in U.S. and Japan fiercepharma
December 19, 2018
With its plan for a spinoff into two companies, Mallinckrodt will create an API and generics operation with a large controlled substances and acetaminophen business and seven manufacturing facilities split between the U.S. and Japan.
Takeda-Shire votes, J&J-Legend and more—FiercePharmaAsia fiercepharma
December 10, 2018
Despite Mallinckrodt’s years-long effort to become a leading maker of innovative drugs, the U.K. company is best known for two of the industry’s biggest scandals.
Oxford regenerative medicine spinout brings on GlaxoSmithKline drug hunter as CSO fiercebiotech
September 11, 2018
Terstappen will work with OxStem’s scientific founders and principal investigators at the University of Oxford across its six discovery programs.
Is now the time for the GlaxoSmithKline consumer spinoff investors have been waiting for? fiercepharma
July 24, 2018
Back in 2016, GlaxoSmithKline’s then-CEO acknowledged that one day the company might divest its consumer health division. Lately, it’s been looking like that day might not be too far away—and now, there's new evidence a spinoff is brewing.
Novartis announces intention to spin off Alcon biospectrumasia
July 09, 2018
The planned spinoff would enable Novartis and Alcon to focus fully on their respective growth strategies, said the company in a statement
Novartis Kicks Alcon Spinoff Decision Down the Road to Mid-2019 biospace
March 28, 2018
Novartis chief executive officer Vasant Narasimhan confirms that any decision about spinning off its Alcon eye care business won’t be made until the first half of 2019.